#interferon signature: doi.org/10.1016/j.ki...
#prognosis signature: doi.org/10.1681/asn....
#interferon signature: doi.org/10.1016/j.ki...
#prognosis signature: doi.org/10.1681/asn....
Our large kidney transcriptomic dataset of #ANCA #glomerulonephritis is now publicly available (www.ncbi.nlm.nih.gov/geo/query/ac...). Used to describe a strong renal interferon signature and a prognosis signature outperforming current classifications (links below). I hope it will be useful! 🚀
22.01.2026 07:54 — 👍 4 🔁 4 💬 1 📌 0
Featuring this year's #ASNJASN Trainee of the Year's award-winning manuscript: "Identification of Renal Transcripts Associated with Kidney Function and Prognosis in ANCA-Associated Vasculitis"
kidney.pub/JASN0779
@benoitbrilland.bsky.social @maineanjoureg.bsky.social
Using kidney transcriptomics, we identified a signature predicting renal survival in #ANCA #vasculitis, outperforming histopathology and opening the way to precision medicine. Thank you @asnpublications.bsky.social for highlighting our work... and for making the article 🔓 OPEN ACCESS 🔓 for 1 month!!
07.11.2025 21:45 — 👍 0 🔁 0 💬 0 📌 0Honored that our work on renal transcriptomics in #ANCA -associated #vasculitis was selected for the #ASNJASN Trainee of the Year award. Very proud to represent the @maineanjoureg.bsky.social and @chuangers.bsky.social !
07.11.2025 21:45 — 👍 0 🔁 0 💬 0 📌 0Using kidney transcriptomics, we identified a robust 12-gene signature predicting renal survival in #ANCA #vasculitis, outperforming histopathology, and opening the way to precision medicine. Thank you for the highlight @asnpublications.bsky.social !
09.09.2025 06:50 — 👍 5 🔁 1 💬 0 📌 0Ex vivo #CRISPR-Cas9 knock out PR3 autoantigen in HSPCs prevents PR3-ANCA-driven neutrophil activation while preserving immune function. While aHSCT would still be required, this opens the door to sustained, drug-free remission in PR3 #ANCA #vasculitis! doi.org/10.1016/j.ki... @kidneyint.bsky.social
25.04.2025 14:06 — 👍 1 🔁 1 💬 0 📌 0This new study shifts the focus from anti-MPO IgG to IgM in #ANCA -associated #vasculitis. IgM autoantibodies not only trigger potent complement activation but also dominate the autoreactive memory B cell pool—revealing a new pathogenic paradigm. Potential implications ⬇️
01.04.2025 12:49 — 👍 1 🔁 1 💬 1 📌 0Targeting endothelial ferroptosis protects kidneys in #ANCA -associated #vasculitis, while systemic inhibition increases inflammation. This is why cell-specific therapies should be prioritised over blanket treatments! @kidneyint.bsky.social doi.org/10.1016/j.ki...
01.04.2025 13:08 — 👍 1 🔁 2 💬 0 📌 0US 🇺🇸 nephrologists, immunologists, pathologists (et al.): there is a place for each of you in France 🇫🇷 … and especially in Angers if you like #vasculitis! www.nature.com/articles/d41...
29.03.2025 21:42 — 👍 5 🔁 1 💬 0 📌 0Kidney transplantation significantly improves survival in #ANCA-associated #vasculitis patients with end-stage kidney disease: 53% lower mortality risk. Our analysis from the french REIN registry ⬇️
24.03.2025 13:27 — 👍 2 🔁 1 💬 0 📌 0Kidney transplantation significantly improves survival in #ANCA-associated #vasculitis patients with end-stage kidney disease: 53% lower mortality risk. Let's improve access to #KidneyTransplant! Read more in our analysis from the french REIN registry doi.org/10.1016/j.ek...
26.02.2025 22:18 — 👍 3 🔁 1 💬 0 📌 0Welcome on Bluesky! @brixsilke.bsky.social @odlerb.bsky.social @thkc.bsky.social @paradise-project.bsky.social. I have included you in the « vasculits lovers » starter pack go.bsky.app/HFADD3c
31.01.2025 14:54 — 👍 5 🔁 1 💬 0 📌 0Vasculitis workshop key dates
Next International #Vasculitis Workshop host @anzvasc.bsky.social is now on Bluesky! See key dates below ⬇️
21.01.2025 17:18 — 👍 2 🔁 1 💬 0 📌 0PEXIVAS post-hoc: no effect of reduced GC dose on kidney recovery in #ANCA #vasculitis. Faster kidney recovery with PLEX but not sustained beyond 3 months (better for subgroup GFR 15-30?). Real PLEX effect vs convection effect? @kronbichlerlab.bsky.social www.kidney-international.org/article/S008...
08.01.2025 16:31 — 👍 4 🔁 1 💬 0 📌 0Infection is the top cause of death in #ANCA -associated #vasculitis, mostly during remission. Death certificates misreport causes, linking EHRs improves accuracy. We need to reduce infection risks through better immunosuppressive therapies www.sciencedirect.com/science/arti...
06.01.2025 15:25 — 👍 0 🔁 1 💬 0 📌 0In #ANCA #vasculitis, 27% patients rated their health better or worse (≥ 20 PGA points) than their physicians did. This discordance highlights the need to address patients' perspectives to improve communication, shared decision-making, and care outcomes. pubmed.ncbi.nlm.nih.gov/39671122/
17.12.2024 14:29 — 👍 1 🔁 1 💬 0 📌 0This study (aacrjournals.org/cancerimmuno...) shows that, in tumor-bearing mice, C5aR blockade boosts anti-PD1 efficacy by enhancing #antitumor immunity. Could these benefits translate to reducing long-term treatment-related adverse events in our #ANCA #vasculitis patients?
16.12.2024 20:25 — 👍 4 🔁 1 💬 0 📌 0First AI-driven model for grading #ANCA -associated #glomerulonephritis lesions achieves 93% accuracy. Grad-CAM heatmaps align with pathologists’ focus, enhancing prognosis reliability. Bonus: the heatmaps look like colorful PET scans of glomeruli! www.kireports.org/article/S246...
12.12.2024 18:18 — 👍 6 🔁 4 💬 1 📌 0Infections affect >50% of #ANCA -associated #vasculitis patients, with risk factors including diabetes, ESKD, kidney/lung involvement and treatment (methylprednisolone pulses, CYC, PLEX). Main site: respiratory system. Early risk management is crucial. doi.org/10.1016/j.au...
10.12.2024 13:47 — 👍 4 🔁 1 💬 0 📌 0
Brace yourself, next Vasculitis Workshop is coming! Key dates:
✅ Abstract submission: 28 March - 19 September 2025
✅ Workshop dates: 21 - 25 February 2026
📍 Melbourne, Australia
vasculitis-melbourne2026.com
Bonjour, bonjour, The Conversation France arrive sur Bluesky ! Ici, pas de breaking news tapageuses ni de buzz éphémères : on mise sur le fond, avec des articles écrits par des chercheurs et chercheuses qui savent de quoi ils parlent, en collaboration avec notre équipe d'excellents journalistes.
21.11.2024 09:23 — 👍 415 🔁 125 💬 22 📌 18
Results of the TAPIR trial: glucocorticoid discontinuation in GPA #ANCA vasculitis.
▶️ higher number of relapse at 6 months for the discontinuation group
▶️ but driven by minor relapses and by subgroup not treated but Rituximab.
Presented by Pr. Peter Merkel #ACR24 (acrabstracts.org/abstract/a-m...)
Hi! Thanks for pinging. I think there is no one-size-fits-all answer. Would consider:
- risk of relapse: GPA/PR3-AAV? ANCA titer overtime? eGFR (= « tolerability » of a future relapse)? Already relapsed? CD19 not that important imo
- risk of SAE, esp. infections (frailty, comorbidities, IgG levels)
Reduced GC dose in #ANCA vasculitis: @terrierben.bsky.social confirms PEXIVAS results in real life: no difference in death/ESKD. Larger composite criteria [see table] (that may be discussed) in favor of standard GC dose, especially for RTX patients and severe AKI ard.bmj.com/content/earl...
26.11.2024 14:29 — 👍 5 🔁 5 💬 0 📌 0Welcome in @terrierben.bsky.social. The #vasculitis family is growing here on Bluesky!
24.11.2024 15:49 — 👍 3 🔁 2 💬 0 📌 0Vasculitis folks are joining! Welcome in @lynnfussner.bsky.social @matsjunek.bsky.social
21.11.2024 16:25 — 👍 4 🔁 0 💬 0 📌 0
Moving from Twitter? Looking for #vasculits #glomerulonephritis lovers?
Starter pack (work in progress): go.bsky.app/HFADD3c. Reply or DM to be added in the list!
My take:
🔹 for detailed emerging therapies, read the #PR3 review
🔸 for detailed pathogenesis, read the #MPO review
Two recent reviews of #ANCA vasculitis with wonderful graphics, and for the first time I think, #PR3 🔹 and #MPO 🔸
phenotypes considered in parallel but SEPARATELY! A new era with individualized treatment is coming for sure!
🔹 pubmed.ncbi.nlm.nih.gov/38574742/
🔸 pubmed.ncbi.nlm.nih.gov/38574743/